|
gptkbp:instance_of
|
gptkb:CAR_T-cell_therapy
|
|
gptkbp:advocacy
|
required
|
|
gptkbp:biological_sample
|
blood-derived T cells
|
|
gptkbp:cell_source
|
patient-derived T cells
|
|
gptkbp:clinical_trial
|
gptkb:Celyad_Oncology
gptkb:2018
Phase 1
response rate
multiple sites
Phase 2 planned
pending publication
NCT03018405
|
|
gptkbp:collaboration
|
various research institutions
|
|
gptkbp:collaborations
|
academic partnerships
|
|
gptkbp:collection
|
clinical data
|
|
gptkbp:developed_by
|
gptkb:Celyad_Oncology
|
|
gptkbp:dosage_form
|
to be defined
|
|
gptkbp:duration
|
variable
|
|
gptkbp:eligibility
|
specific criteria apply
|
|
gptkbp:funding
|
secured funding
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CYAD-02
|
|
gptkbp:impact
|
potential to improve outcomes
|
|
gptkbp:indication
|
gptkb:Oncology
gptkb:non-Hodgkin_lymphoma
|
|
gptkbp:invention
|
patented
|
|
gptkbp:investigates
|
clinical researchers
|
|
gptkbp:is_effective_against
|
preliminary results available
|
|
gptkbp:manufacturing_process
|
ex vivo expansion
|
|
gptkbp:market_position
|
not commercially available
|
|
gptkbp:mechanism_of_action
|
engineered T cells
|
|
gptkbp:objective
|
evaluate safety and efficacy
|
|
gptkbp:patient_population
|
adult patients
|
|
gptkbp:project
|
early clinical development
|
|
gptkbp:publication
|
multiple peer-reviewed articles
|
|
gptkbp:regulatory_compliance
|
investigational
|
|
gptkbp:related_products
|
filed
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_ethics_approval
|
obtained
|
|
gptkbp:research_focus
|
gptkb:immunotherapy
|
|
gptkbp:research_output
|
to be analyzed
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:safety_features
|
under investigation
|
|
gptkbp:safety_measures
|
ongoing
|
|
gptkbp:side_effect
|
to be determined
|
|
gptkbp:targets
|
gptkb:CD19
|
|
gptkbp:therapeutic_goal
|
cancer remission
|
|
gptkbp:treatment
|
gptkb:Cell
monitored regularly
under evaluation
standardized protocol
|
|
gptkbp:type
|
autologous T cell therapy
|
|
gptkbp:used_for
|
treatment of hematological malignancies
|
|
gptkbp:bfsParent
|
gptkb:Celyad
|
|
gptkbp:bfsLayer
|
6
|